FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138796064> ?p ?o ?g. }

• W3138796064 endingPage "S342" @default.
• W3138796064 startingPage "S342" @default.
• W3138796064 abstract "PurposeOne of the most common challenges facing the transplant population are invasive fungal infections including aspergillosis, mucormycosis, and those due to endemic fungi. Fungal prophylaxis is becoming standard of practice to limit development of invasive fungal infections. Isavuconazole and posaconazole are commonly used antifungal medications as both prophylaxis and treatment. These drugs are approved for oral and intravenous (IV) administration however, use via alternative enteric routes have not been well studied.MethodsA retrospective chart review was conducted of transplant patients receiving triazole therapy for prophylaxis or treatment over a seven month period. Patients with an inability to swallow oral medications switched during their course of care from IV therapy to non-oral enteric administration of isavuconazole or posaconazole via nasogastric, orogastric, percutaneous endoscopic gastrostomy (PEG), or percutaneous endoscopic gastrojejunostomy (PEG-J) tubes were included in the study.ResultsWe identified 17 patients administered isavuconazole or posaconazole via non-oral enteric routes (Table 1). The indication for therapy was primarily for prophylaxis after single or double lung transplantation. The majority (83%) of cases were therapeutic at the time of their first drug level assessment, with a mean level of 2.47 +/- 0.71 for isavuconazole and 0.84 +/- 1.03 for posaconazole. All patients not therapeutic at initial assessment had doses increased and subsequently achieved therapeutic levels.ConclusionOur case series shows isavuconazole and posaconazole can be administered via non-oral enteric routes with therapeutic drug monitoring to achieve acceptable serum drug concentrations and avoid prolonged IV therapy in a transplant population. Given the increasing complexity and age of transplant recipients, continued studies are needed to address alternative antifungal dosing regimens. One of the most common challenges facing the transplant population are invasive fungal infections including aspergillosis, mucormycosis, and those due to endemic fungi. Fungal prophylaxis is becoming standard of practice to limit development of invasive fungal infections. Isavuconazole and posaconazole are commonly used antifungal medications as both prophylaxis and treatment. These drugs are approved for oral and intravenous (IV) administration however, use via alternative enteric routes have not been well studied. A retrospective chart review was conducted of transplant patients receiving triazole therapy for prophylaxis or treatment over a seven month period. Patients with an inability to swallow oral medications switched during their course of care from IV therapy to non-oral enteric administration of isavuconazole or posaconazole via nasogastric, orogastric, percutaneous endoscopic gastrostomy (PEG), or percutaneous endoscopic gastrojejunostomy (PEG-J) tubes were included in the study. We identified 17 patients administered isavuconazole or posaconazole via non-oral enteric routes (Table 1). The indication for therapy was primarily for prophylaxis after single or double lung transplantation. The majority (83%) of cases were therapeutic at the time of their first drug level assessment, with a mean level of 2.47 +/- 0.71 for isavuconazole and 0.84 +/- 1.03 for posaconazole. All patients not therapeutic at initial assessment had doses increased and subsequently achieved therapeutic levels. Our case series shows isavuconazole and posaconazole can be administered via non-oral enteric routes with therapeutic drug monitoring to achieve acceptable serum drug concentrations and avoid prolonged IV therapy in a transplant population. Given the increasing complexity and age of transplant recipients, continued studies are needed to address alternative antifungal dosing regimens." @default.
• W3138796064 created "2021-03-29" @default.
• W3138796064 creator A5003508483 @default.
• W3138796064 creator A5060910250 @default.
• W3138796064 creator A5012745803 @default.
• W3138796064 date "2021-04-01" @default.
• W3138796064 modified "2023-09-27" @default.
• W3138796064 title "Enteral Delivery of Posaconazole or Izavuconazole in Patients with Inability to Swallow Tablets Can Achieve Therapeutic Drug Levels: A Single Center Pilot Study" @default.
• W3138796064 doi "https://doi.org/10.1016/j.healun.2021.01.963" @default.
• W3138796064 hasPublicationYear "2021" @default.
• W3138796064 type Work @default.
• W3138796064 sameAs 3138796064 @default.
• W3138796064 citedByCount "0" @default.
• W3138796064 crossrefType "journal-article" @default.
• W3138796064 hasAuthorship W3138796064A5003508483 @default.
• W3138796064 hasAuthorship W3138796064A5012745803 @default.
• W3138796064 hasAuthorship W3138796064A5060910250 @default.
• W3138796064 hasBestOaLocation W31387960641 @default.
• W3138796064 hasConcept C126322002 @default.
• W3138796064 hasConcept C141071460 @default.
• W3138796064 hasConcept C16005928 @default.
• W3138796064 hasConcept C177713679 @default.
• W3138796064 hasConcept C203014093 @default.
• W3138796064 hasConcept C2776391196 @default.
• W3138796064 hasConcept C2778566413 @default.
• W3138796064 hasConcept C2779548794 @default.
• W3138796064 hasConcept C2780035454 @default.
• W3138796064 hasConcept C2780272996 @default.
• W3138796064 hasConcept C2780690907 @default.
• W3138796064 hasConcept C2908647359 @default.
• W3138796064 hasConcept C71924100 @default.
• W3138796064 hasConcept C98274493 @default.
• W3138796064 hasConcept C99454951 @default.
• W3138796064 hasConceptScore W3138796064C126322002 @default.
• W3138796064 hasConceptScore W3138796064C141071460 @default.
• W3138796064 hasConceptScore W3138796064C16005928 @default.
• W3138796064 hasConceptScore W3138796064C177713679 @default.
• W3138796064 hasConceptScore W3138796064C203014093 @default.
• W3138796064 hasConceptScore W3138796064C2776391196 @default.
• W3138796064 hasConceptScore W3138796064C2778566413 @default.
• W3138796064 hasConceptScore W3138796064C2779548794 @default.
• W3138796064 hasConceptScore W3138796064C2780035454 @default.
• W3138796064 hasConceptScore W3138796064C2780272996 @default.
• W3138796064 hasConceptScore W3138796064C2780690907 @default.
• W3138796064 hasConceptScore W3138796064C2908647359 @default.
• W3138796064 hasConceptScore W3138796064C71924100 @default.
• W3138796064 hasConceptScore W3138796064C98274493 @default.
• W3138796064 hasConceptScore W3138796064C99454951 @default.
• W3138796064 hasIssue "4" @default.
• W3138796064 hasLocation W31387960641 @default.
• W3138796064 hasOpenAccess W3138796064 @default.
• W3138796064 hasPrimaryLocation W31387960641 @default.
• W3138796064 hasRelatedWork W1920493799 @default.
• W3138796064 hasRelatedWork W2079989445 @default.
• W3138796064 hasRelatedWork W2087960503 @default.
• W3138796064 hasRelatedWork W2095276293 @default.
• W3138796064 hasRelatedWork W2116604032 @default.
• W3138796064 hasRelatedWork W2137973251 @default.
• W3138796064 hasRelatedWork W2790418987 @default.
• W3138796064 hasRelatedWork W4220734204 @default.
• W3138796064 hasRelatedWork W4241497131 @default.
• W3138796064 hasRelatedWork W4283721701 @default.
• W3138796064 hasVolume "40" @default.
• W3138796064 isParatext "false" @default.
• W3138796064 isRetracted "false" @default.
• W3138796064 magId "3138796064" @default.
• W3138796064 workType "article" @default.